Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2025 01:00 ET | Source: Augustine Therapeutics

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease

AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology...